PCG
MRNA icon

Prosperity Consulting Group’s Moderna MRNA Stock Holding History

Prosperity Consulting Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,748
Closed -$208K – 467
2024
Q2 		$208K Buy
+1,748
New +$221K 0.03% 294

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Prosperity Consulting Group's MRNA Position: Q3 2024 in Review

Prosperity Consulting Group sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,748 shares — an estimated $208K sold.

Prosperity Consulting Group first reported a position in MRNA in Q2 2024 and held it in 1 quarter. The position peaked at $208K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Prosperity Consulting Group reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Prosperity Consulting Group sold 1,748 Moderna shares in Q3 2024, an estimated $208K.
  • Prosperity Consulting Group first reported a position in Moderna in Q2 2024 and held it in 1 quarter.
  • Prosperity Consulting Group's Moderna position peaked at $208K in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Prosperity Consulting Group's 13F filing for Q3 2024, filed 15 Oct 2024.